secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2026-01-21T23:59:59+00:00
Accession:  0000320017-26-000006
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata to be acquired by Kuva Labs for $4.00 cash/share + up to $2 CVRs; ~85% premium
--------------------------------------------------------------------------------

- All-cash tender offer at $4.00/share plus two non-tradeable CVRs worth up to $2/share tied to certepetide milestones.
- Cash portion represents ~85% premium over last close; total potential consideration ~180% premium.
- Kuva has committed financing and will not condition offer on funding; break fee of $2 million for certain failures.
- Definitive purchase agreement targeted by Feb 27, 2026; boards of both companies unanimously approved term sheet.
- Rollover shares may be contributed to Kuva in exchange for equity, and standstill restricts Kuva for 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001726000006/0000320017-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001726000006/clbs-20260120.htm
  HTML page:      https://secwatch.observer/filing/0000320017-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer